Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Molecular Partners AG. (5/20/16). "Press Release: Molecular Partners to Present at the UBS Global Healthcare Conference 2016 in New York". Zürich-Schlieren.

Organisations Organisation Molecular Partners AG (SIX: MOLN)
  Organisation 2 UBS Investment Bank AG
  Group UBS (Group)
Products Product UBS Global Healthcare Conference 2016 New York
  Product 2 DARPin (Designed Ankyrin Repeat Protein)
Index term Index term Molecular Partners–UBS: investor conference, 201605 supply service Molecular Partners presents at UBS Global Healthcare Conference NY
Persons Person Zahnd, Christian (Molecular Partners 200708 CEO)
  Person 2 Emmenegger, Andreas (Molecular Partners 201603 CFO)

Molecular Partners AG (ticker: MOLN) today announced that it will present at the UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 2:00 PM Eastern Time (8:00 PM CET). The presentation, followed by a breakout session, will be hosted by Dr. Christian Zahnd, CEO of Molecular Partners.

The presentation will be available for viewing via live webcast and can be accessed on the day through this link. A copy of the presentation handout as well as a replay of the webcast will be made available on the company’s website under the Investors section.

The replay will be available for 180 days following the presentation.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPins. DARPins are potent, specific, and versatile small-protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.

Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors. For more information regarding Molecular Partners AG, go to:

For further details, please contact:

Dr. Christian Zahnd, CEO
Tel: +41 (0) 44 755 77 00

Andreas Emmenegger, CFO
Tel: +41 (0) 44 755 77 00

Rolf Schläpfer
Tel: +41 (0) 43 344 42 42

Record changed: 2017-07-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Molecular Partners AG (SIX: MOLN)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top